#1 Clinical Trials Search in Europe

Study on the Effects of Telmisartan, Amlodipine, and Hydrochlorothiazide on Blood Pressure in Patients with Hypertension

3 1 1 1

What is this study about?

This clinical trial is focused on studying the effects of a treatment for arterial hypertension, commonly known as high blood pressure. The study will use a combination of medications in a single pill, specifically telmisartan and amlodipine, as well as a combination of telmisartan, amlodipine, and hydrochlorothiazide. These medications are designed to help lower blood pressure and improve blood pressure control over a 24-hour period.

The purpose of the study is to assess how effective these single-pill combinations are in reducing blood pressure after 16 weeks of treatment in patients with different grades of high blood pressure. Participants will take the medication orally, and the study will monitor changes in their blood pressure throughout the day and during office visits. The study will also look at how blood pressure varies over 24 hours and how well it is controlled during office visits.

Participants in the study will be monitored over a period of 16 weeks. During this time, they will have regular check-ups to measure their blood pressure and assess the effectiveness of the treatment. The study aims to provide valuable information on how these medications can help manage high blood pressure and improve overall health outcomes for patients with this condition.

1 initial visit and assessment

Upon joining the clinical trial, you will attend an initial visit. During this visit, your eligibility will be confirmed based on your medical history and current health status.

Your blood pressure will be measured using a device that monitors it over 24 hours. This is to ensure that your average blood pressure meets the study requirements.

2 medication allocation

If eligible, you will be assigned a medication. The study involves a single-pill combination of telmisartan and amlodipine, or a combination of telmisartan, amlodipine, and hydrochlorothiazide.

These medications are taken orally in the form of tablets. The specific dosage and combination will be determined by the study protocol.

3 treatment phase

You will take the assigned medication daily for a period of 16 weeks. It is important to adhere to the prescribed dosage and schedule.

Regular monitoring of your blood pressure will occur throughout this period to assess the effectiveness of the treatment.

4 follow-up visits

You will attend follow-up visits at weeks 4, 8, 12, and 16. During these visits, your blood pressure will be measured, and any changes will be recorded.

These visits are crucial for monitoring your response to the medication and ensuring your safety throughout the trial.

5 final assessment

At the end of the 16-week treatment period, a final assessment will be conducted. This will include a comprehensive evaluation of your blood pressure and overall health.

The results will help determine the effectiveness of the medication in managing arterial hypertension.

Who Can Join the Study?

  • Patients with diagnosed Grade 1, Grade 2, or Grade 3 Arterial Hypertension at both the first and second visits.
  • Average 24-hour Systolic Blood Pressure (SBP) of 130 mmHg or higher and/or average 24-hour Diastolic Blood Pressure (DBP) of 80 mmHg or higher, measured using a device that monitors blood pressure over 24 hours.
  • Patients who have not been treated for high blood pressure before, or those whose blood pressure is not controlled with their current single or dual medication (except those already taking telmisartan and amlodipine).
  • Female or male patients who are 18 years or older.
  • Patients who can follow the study rules and procedures, as judged by the study doctor.
  • Patients who have been informed about the study and have voluntarily signed a form agreeing to participate.
  • Patients who have signed a consent form allowing the collection and use of their personal data for analysis and reporting of the study results.

Who Cannot Join the Study?

  • Patients with any other serious health conditions that might interfere with the study.
  • Patients who are pregnant or breastfeeding.
  • Patients who have had an allergic reaction to any of the study medications.
  • Patients who are currently participating in another clinical trial.
  • Patients with a history of drug or alcohol abuse.
  • Patients with uncontrolled diabetes or other uncontrolled medical conditions.
  • Patients with severe liver or kidney disease.
  • Patients with a history of heart attack or stroke in the last six months.
  • Patients who have had a major surgery in the last three months.
  • Patients with a history of cancer in the last five years, except for certain skin cancers.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Niepubliczny Zaklad Opieki Zdrowotnej Salmed Leczna Poland

Other Sites

Site Name City Country Status
Splosna Bolnisnica Jesenice Jesenice Slovenia
B&R Clinical Sp. z o.o. Kielce Poland
Verboten Kopriva Renata Ordinacija Interne Medicine Litija Slovenia
Policlinica Centrum Sp. z o.o. Gdynia Poland
Biatros Kft. Biatorbagy Hungary
MC MEDICOR mednarodni center za kardiovaskularne bolezni d.d. Ljubljana Slovenia
Md Clinic Sp. z o.o. Warsaw Poland
Nhcxvcavdsjj Zjlolp Oykrau Zgrzgteynq Mlcjjjs Sc Cd Podkowa Leśna Poland
Vtqyjths 2bcw Beq Tiszacsege Hungary
Etpliwdgsgsp Kfuh Makó Hungary
Mzozozwd Sxc z odmm Oświęcim Poland

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Hungary Hungary
Not recruiting
01.12.2023
Poland Poland
Not recruiting
01.12.2023
Slovenia Slovenia
Not recruiting
01.12.2023

Trial locations

Investigated drugs:

Telmisartan is a medication used to help lower high blood pressure. It works by relaxing blood vessels so that blood can flow more easily. This helps to reduce the risk of serious health problems like heart attacks and strokes.

Amlodipine is another medication that helps to lower blood pressure. It is a type of drug known as a calcium channel blocker. It helps to relax and widen blood vessels, making it easier for the heart to pump blood around the body.

Hydrochlorothiazide is a medication that helps to lower blood pressure by removing excess salt and water from the body. It is a type of diuretic, sometimes called a “water pill,” and it helps to reduce the amount of fluid in the blood vessels, which lowers blood pressure.

Arterial hypertension – Arterial hypertension, commonly known as high blood pressure, is a condition where the force of the blood against the artery walls is consistently too high. It often develops over many years and can affect nearly everyone eventually. The condition is characterized by elevated systolic and/or diastolic blood pressure levels. As it progresses, it can lead to damage of blood vessels and organs, particularly the heart, brain, kidneys, and eyes. Over time, the heart may have to work harder to pump blood, which can lead to heart-related complications. The progression of arterial hypertension can be influenced by factors such as age, lifestyle, and genetics.

Trial ID:
2023-504812-13-00
Protocol code:
KCT02/2023-SATELLITE
Trial Phase:
Human Pharmacology (Phase I) – Other

Other Trials to Consider

  • Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Bulgaria Croatia Czechia Denmark +17

  • A study to evaluate the effect of baxdrostat and dapagliflozin in reducing protein in the urine for patients with chronic kidney disease and high blood pressure

    Recruiting

    2 1 1
    Investigated drugs:
    Bulgaria Spain